Literature DB >> 22308159

Hepatitis e virus infection in Iranian kidney-transplant patients.

Nassim Kamar1.   

Abstract

Entities:  

Keywords:  Hepatitis E; Kidney Transplantation; Patients

Year:  2011        PMID: 22308159      PMCID: PMC3269063          DOI: 10.5812/kowsar.1735143x.791

Source DB:  PubMed          Journal:  Hepat Mon        ISSN: 1735-143X            Impact factor:   0.660


× No keyword cloud information.
Dear Editor, Hepatitis E virus infection is an endemic disease in developing and industrialized countries [1],and is responsible for acute and chronic hepatitis. Genotype 1 is more prevalent in developing countries, whereas genotype 3 is more common in developed countries [1]. Chronic genotype 3 HEV infection can occur in solid-organ transplant patients [2], hematological patients who receive chemotherapy [3], and HIV-positive patients [4]. In the past several years, HEV infection in organ transplant patients has garnered much interest. After kidney transplantation, HEV-related liver fibrosis can lead rapidly to cirrhosis [5]. The use of tacrolimus, rather than cyclosporine A, and a low platelet count at HEV diagnosis have been identified as predictive factors for chronic HEV infection [6]. However, decreased immunosuppressant dose can result in HEV clearance in nearly one-third of patients [6]. In addition, ribavirin monotherapy can be efficacious in treating chronic HEV infection [7]. In this issue of Hepatitis Monthly, Khameneh et al. determined the prevalence of anti-HEV IgG in 91 randomly selected Iranian kidney transplant patients [8]. The HEV seroprevalence was 30.8%, although there was poor sensitivity and specificity between HEV serological assays [9]. However, this study on seroprevalence in an Iranian kidney transplant population is a first step toward improving the assessment of HEV infection in this setting. Unfortunately, as discussed by the authors, HEV RNA was not measured in this study. Consequently, the authors were unable to determine whether some patients developed chronic hepatitis—a significant shortcoming, because 45.1% of patients had unexplained increases in liver function tests [8]. The measurement of HEV genotype may also be valuable, because, similar to what has been observed in Europe, Khameneh et al. found more positive HEV serologies in older patients [8]. In summary, Khamaneh et al. noted a high seroprevalence rate of HEV in an Iranian kidney transplant population. Further studies are needed to evaluate the impact of HEV infection in this population.
  9 in total

1.  A comparison of two commercially available anti-HEV IgG kits and a re-evaluation of anti-HEV IgG seroprevalence data in developed countries.

Authors:  Richard Bendall; Vic Ellis; Samreen Ijaz; Rachel Ali; Harry Dalton
Journal:  J Med Virol       Date:  2010-05       Impact factor: 2.327

2.  Chronic hepatitis after hepatitis E virus infection in a patient with non-Hodgkin lymphoma taking rituximab.

Authors:  Laurence Ollier; Nathalie Tieulie; Frédérick Sanderson; Philippe Heudier; Valérie Giordanengo; Jean-Gabriel Fuzibet; Elisabeth Nicand
Journal:  Ann Intern Med       Date:  2009-03-17       Impact factor: 25.391

3.  Persistent carriage of hepatitis E virus in patients with HIV infection.

Authors:  Harry R Dalton; Richard P Bendall; Frances E Keane; Richard S Tedder; Samreen Ijaz
Journal:  N Engl J Med       Date:  2009-09-03       Impact factor: 91.245

4.  Influence of immunosuppressive therapy on the natural history of genotype 3 hepatitis-E virus infection after organ transplantation.

Authors:  Nassim Kamar; Florence Abravanel; Janick Selves; Cyril Garrouste; Laure Esposito; Laurence Lavayssière; Olivier Cointault; David Ribes; Isabelle Cardeau; Marie Béatrice Nogier; Jean Michel Mansuy; Fabrice Muscari; Jean Marie Peron; Jacques Izopet; Lionel Rostaing
Journal:  Transplantation       Date:  2010-02-15       Impact factor: 4.939

5.  Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants.

Authors:  Nassim Kamar; Cyril Garrouste; Elizabeth B Haagsma; Valérie Garrigue; Sven Pischke; Cécile Chauvet; Jérome Dumortier; Amélie Cannesson; Elisabeth Cassuto-Viguier; Eric Thervet; Filomena Conti; Pascal Lebray; Harry R Dalton; Robert Santella; Nada Kanaan; Marie Essig; Christiane Mousson; Sylvie Radenne; Anne Marie Roque-Afonso; Jacques Izopet; Lionel Rostaing
Journal:  Gastroenterology       Date:  2011-02-24       Impact factor: 22.682

6.  Ribavirin therapy inhibits viral replication on patients with chronic hepatitis e virus infection.

Authors:  Nassim Kamar; Lionel Rostaing; Florence Abravanel; Cyril Garrouste; Sebastien Lhomme; Laure Esposito; Grégoire Basse; Olivier Cointault; David Ribes; Marie Béatrice Nogier; Laurent Alric; Jean Marie Peron; Jacques Izopet
Journal:  Gastroenterology       Date:  2010-08-11       Impact factor: 22.682

Review 7.  Hepatitis E: an emerging infection in developed countries.

Authors:  Harry R Dalton; Richard Bendall; Samreen Ijaz; Malcolm Banks
Journal:  Lancet Infect Dis       Date:  2008-11       Impact factor: 25.071

8.  Hepatitis E virus and chronic hepatitis in organ-transplant recipients.

Authors:  Nassim Kamar; Janick Selves; Jean-Michel Mansuy; Leila Ouezzani; Jean-Marie Péron; Joëlle Guitard; Olivier Cointault; Laure Esposito; Florence Abravanel; Marie Danjoux; Dominique Durand; Jean-Pierre Vinel; Jacques Izopet; Lionel Rostaing
Journal:  N Engl J Med       Date:  2008-02-21       Impact factor: 91.245

9.  Seroprevalence of hepatitis E among Iranian renal transplant recipients.

Authors:  Zakieh Rostamzadeh Khameneh; Nariman Sepehrvand; Sima Masudi
Journal:  Hepat Mon       Date:  2011-08       Impact factor: 0.660

  9 in total
  4 in total

Review 1.  Epidemiology of hepatitis E virus in Iran.

Authors:  Reza Taherkhani; Fatemeh Farshadpour
Journal:  World J Gastroenterol       Date:  2016-06-14       Impact factor: 5.742

2.  Seroprevalence of hepatitis e virus varies considerably among chinese provinces.

Authors:  Chen Dong; Xing Dai; Jiuhong Liang; Min Dong; Jihong Meng
Journal:  Hepat Mon       Date:  2012-06-30       Impact factor: 0.660

3.  Author's Reply: Hepatitis E Virus Infection in Iranian Kidney-Transplant Patients.

Authors:  Zakieh Rostamzadeh Khameneh; Nariman Sepehrvand
Journal:  Hepat Mon       Date:  2011-11-30       Impact factor: 0.660

Review 4.  Epidemiology of Hepatitis E in Pregnant Women and Children in Iran: A General Overview.

Authors:  Reza Taherkhani; Fatemeh Farshadpour
Journal:  J Clin Transl Hepatol       Date:  2016-08-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.